# COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.

> **NCT02395237** · PHASE1 · WITHDRAWN · sponsor: **Pharmaceutical Research Unit, Jordan**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** : Amaryl® M IR 2/1000

## Key facts

- **NCT ID:** NCT02395237
- **Lead sponsor:** Pharmaceutical Research Unit, Jordan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-05
- **Primary completion:** 2015-05
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2020-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02395237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02395237, "COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02395237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*